Trial Profile
Xelox [capecitabine + oxaliplatin] plus cetuximab as first-line therapy in patients with metastatic colorectal cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 Nov 2005 New trial record.